Statin Use May Decrease Barrett’s Esophagus Risk

Published Online: Friday, July 11, 2014
Follow Pharmacy_Times:
Statin use may decrease the risk of Barrett’s esophagus, according to the results of a study published online on May 2, 2014, in Gastroenterology.

The case-control study compared 303 patients diagnosed with Barrett’s esophagus with a group of selective endoscopy controls and a group of primary care controls to analyze the impact of statins on the risk for the condition. To determine statin use, researchers of the study analyzed pharmacy records during a 10-year period before patients were diagnosed with Barrett’s esophagus. Patients were recruited from primary care clinics at a Veterans Affairs center and were eligible for colonoscopy screenings or had been scheduled for elective esophagogastroduodenoscopy.

Overall, 57.4% of Barrett’s esophagus patients used statins, compared with 64.9% of endoscopy controls and 71.3% of primary care controls. The results indicated that statin use was associated with a significantly lower risk for Barrett’s esophagus compared with the combined control groups. The risk was especially decreased among obese patients who used statins and for Barrett’s esophagus segments of 3 cm or more. The study did not find a significant association between Barrett’s esophagus and nonstatin lipid-lowering medications.


Related Articles
The FDA today approved AstraZeneca’s naloxegol (Movantik) treatment for opioid-induced constipation in adults with chronic noncancer pain.
The My GI Health tool tracks symptoms of gastroesophageal reflux disease over time, helping clinicians save time and improve patient care.
In several countries, increases in the incidence of inflammatory bowel disease have been observed closely following regulatory approval of sucralose.
Patients who receive statins soon after acute coronary syndrome are 24% less likely to experience unstable angina after 4 months.
Latest Issues
$auto_registration$